CA2131355C - Production d'une immunoglobuline codee par un gene unique - Google Patents

Production d'une immunoglobuline codee par un gene unique Download PDF

Info

Publication number: CA2131355C
Authority: CA; Canada
Prior art keywords: polypeptide; variable region; chain variable; immunoglobulin; heavy chain
Prior art date: 1994-09-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2131355

Other languages

English (en)

Other versions

CA2131355A1 (fr

Inventor

Syed V. S. Kashmiri

Liming Shu

Jeffrey Schlom

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

THE GOVERNMENT OF THE UNITED STATES OF AMERICA

Original Assignee

THE GOVERNMENT OF THE UNITED STATES OF AMERICA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-01

Filing date

1994-09-01

Publication date

2001-04-17

1994-09-01 Application filed by THE GOVERNMENT OF THE UNITED STATES OF AMERICA filed Critical THE GOVERNMENT OF THE UNITED STATES OF AMERICA

1994-09-01 Priority to CA 2131355 priority Critical patent/CA2131355C/fr

1996-03-02 Publication of CA2131355A1 publication Critical patent/CA2131355A1/fr

2001-04-17 Application granted granted Critical

2001-04-17 Publication of CA2131355C publication Critical patent/CA2131355C/fr

2014-09-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108060003951 Immunoglobulin Proteins 0.000 title abstract description 14
102000018358 immunoglobulin Human genes 0.000 title abstract description 14
238000004519 manufacturing process Methods 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 64
230000027455 binding Effects 0.000 claims abstract description 52
210000004027 cell Anatomy 0.000 claims abstract description 52
239000000427 antigen Substances 0.000 claims abstract description 37
108091007433 antigens Proteins 0.000 claims abstract description 37
102000036639 antigens Human genes 0.000 claims abstract description 37
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract description 19
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 14
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 13
210000004962 mammalian cell Anatomy 0.000 claims abstract description 11
229920001184 polypeptide Polymers 0.000 claims description 51
102000004196 processed proteins & peptides Human genes 0.000 claims description 51
206010028980 Neoplasm Diseases 0.000 claims description 32
108091033319 polynucleotide Proteins 0.000 claims description 29
239000002157 polynucleotide Substances 0.000 claims description 29
102000040430 polynucleotide Human genes 0.000 claims description 29
101150047061 tag-72 gene Proteins 0.000 claims description 18
238000000034 method Methods 0.000 claims description 14
239000002773 nucleotide Substances 0.000 claims description 10
125000003729 nucleotide group Chemical group 0.000 claims description 10
108090000288 Glycoproteins Proteins 0.000 claims description 8
102000003886 Glycoproteins Human genes 0.000 claims description 8
239000000539 dimer Substances 0.000 claims description 6
206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
201000000050 myeloid neoplasm Diseases 0.000 claims description 5
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims description 3
238000010367 cloning Methods 0.000 claims description 3
230000002538 fungal effect Effects 0.000 claims description 3
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
235000018417 cysteine Nutrition 0.000 claims 9
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 9
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
235000001014 amino acid Nutrition 0.000 claims 2
150000001413 amino acids Chemical class 0.000 claims 2
239000013612 plasmid Substances 0.000 claims 1
230000001131 transforming effect Effects 0.000 claims 1
210000005253 yeast cell Anatomy 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 38
102000004169 proteins and genes Human genes 0.000 abstract description 23
230000001225 therapeutic effect Effects 0.000 abstract description 8
238000001890 transfection Methods 0.000 abstract description 8
238000013459 approach Methods 0.000 abstract description 5
201000009030 Carcinoma Diseases 0.000 abstract description 4
238000001415 gene therapy Methods 0.000 abstract description 4
239000003153 chemical reaction reagent Substances 0.000 abstract description 3
238000010276 construction Methods 0.000 abstract description 2
239000012531 culture fluid Substances 0.000 abstract description 2
230000001461 cytolytic effect Effects 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 20
241001529936 Murinae Species 0.000 description 19
239000012636 effector Substances 0.000 description 17
201000011510 cancer Diseases 0.000 description 15
238000003556 assay Methods 0.000 description 13
239000012634 fragment Substances 0.000 description 13
108020004414 DNA Proteins 0.000 description 8
230000000694 effects Effects 0.000 description 7
210000004408 hybridoma Anatomy 0.000 description 7
230000002068 genetic effect Effects 0.000 description 5
238000000746 purification Methods 0.000 description 5
102000014914 Carrier Proteins Human genes 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
101710120037 Toxin CcdB Proteins 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
108091008324 binding proteins Proteins 0.000 description 4
239000013615 primer Substances 0.000 description 4
239000013598 vector Substances 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
206010014733 Endometrial cancer Diseases 0.000 description 3
206010014759 Endometrial neoplasm Diseases 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
241000701024 Human betaherpesvirus 5 Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
201000003914 endometrial carcinoma Diseases 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
238000010586 diagram Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
230000002476 tumorcidal effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000652582 Homo sapiens Antigen peptide transporter 2 Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000713862 Moloney murine sarcoma virus Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
102000025171 antigen binding proteins Human genes 0.000 description 1
108091000831 antigen binding proteins Proteins 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000005889 cellular cytotoxicity Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000054264 human TAP2 Human genes 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
239000013014 purified material Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

CA 2131355 1994-09-01 1994-09-01 Production d'une immunoglobuline codee par un gene unique Expired - Lifetime CA2131355C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2131355 CA2131355C (fr)	1994-09-01	1994-09-01	Production d'une immunoglobuline codee par un gene unique

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2131355 CA2131355C (fr)	1994-09-01	1994-09-01	Production d'une immunoglobuline codee par un gene unique

Publications (2)

Publication Number	Publication Date
CA2131355A1 CA2131355A1 (fr)	1996-03-02
CA2131355C true CA2131355C (fr)	2001-04-17

Family

ID=4154274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2131355 Expired - Lifetime CA2131355C (fr)	1994-09-01	1994-09-01	Production d'une immunoglobuline codee par un gene unique

Country Status (1)

Country	Link
CA (1)	CA2131355C (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6818749B1 (en)	1998-10-31	2004-11-16	The United States Of America As Represented By The Department Of Health And Human Services	Variants of humanized anti carcinoma monoclonal antibody cc49
EP1532162B1 (fr)	2002-06-28	2013-08-07	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
WO2005021594A2 (fr)	2003-08-29	2005-03-10	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Variants a peine immunogenes de l'anticorps humanise a greffe sdr cc49 et leur utilisation

1994
- 1994-09-01 CA CA 2131355 patent/CA2131355C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2131355A1 (fr)	1996-03-02

Publication	Publication Date	Title
US5892019A (en)	1999-04-06	Production of a single-gene-encoded immunoglobulin
Shu et al.	1993	Secretion of a single-gene-encoded immunoglobulin from myeloma cells.
Morrison et al.	1989	Genetically engineered antibody molecules
CN113416258B (zh)	2023-08-29	一种多特异性抗体及其制备方法和用途
Kostelny et al.	1992	Formation of a bispecific antibody by the use of leucine zippers.
US5576184A (en)	1996-11-19	Production of chimeric mouse-human antibodies with specificity to human tumor antigens
CA1341614C (fr)	2011-05-24	Proteines multifonctions a cible definie
Shalaby et al.	1992	Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.
Müller et al.	1998	The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies
EP0338745B1 (fr)	1995-03-01	Procédé de production de protéines par l'ADN recombinant
JP2675380B2 (ja)	1997-11-12	組換ｄｎａ産物及び方法
US5258498A (en)	1993-11-02	Polypeptide linkers for production of biosynthetic proteins
AU634314B2 (en)	1993-02-18	Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
CA1341351C (fr)	2002-03-26	Production d'anticorps chimeres souris-homme, specifiques pour les antigenes tumoraux chez l'homme
US4978745A (en)	1990-12-18	Immunoreactive heterochain antibodies
US20090088561A1 (en)	2009-04-02	Enhancing the circulating half-life of antibody-based fusion proteins
EP0256654A2 (fr)	1988-02-24	Immunoglobuline chimère murine-humaine, spécifique pour l' antigène 17-1A associés aux tumeurs
EP3421500B1 (fr)	2025-03-05	Procédé d'expression et de préparation d'une protéine de fusion d'anticorps
WO1999043713A1 (fr)	1999-09-02	Amelioration de la demi-vie circulante de proteines hybrides a base d'anticorps
WO1992022324A1 (fr)	1992-12-23	Fragments d'anticorps produits par des microbes et leurs conjugues
AU2018241881B2 (en)	2024-10-10	Stable multispecific antibodies
AU2018206229B2 (en)	2024-09-19	A polypeptide linker for preparing multispecific antibodies
Lee et al.	1999	Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions
US5965405A (en)	1999-10-12	Method for producing Fv fragments in eukaryotic cells
JP7365654B2 (ja)	2023-10-20	抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体

Legal Events

Date	Code	Title	Description
1996-10-23	EEER	Examination request
2014-11-04	MKEX	Expiry	Effective date: 20140902